Abstract: The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonsists, STAT3 activators, and an agent that increase nitric oxide, alone or in combination, to treat nerve deficit conditions.

Abstract: Cellulose materials and methods of making the cellulose materials are described herein. The method can include contacting a cotton fabric with an oxidizing system to obtain an oxidized cotton material and processing the oxidized cotton material to form the cellulose material. The oxidizing system can include an aqueous mixture of a N-oxyl compound and a hypochlorite compound. During oxidation, the p11 of the aqueous mixture can be maintained at from 8.5 to 11. Cellulose products can be formed from the cellulose materials. For example, the cellulose products can be used to form a packaging material, a biomedical device or implant, a drug delivery material, a fiber, a textile material, a template for electronic components, or a separation membrane. Methods of making the cellulose product include dissolving or suspending an active ingredient in a medium comprising the cellulose material.

Abstract: In one aspect, molecular sensors and methods of making molecular sensors are described herein. In some embodiments, such a sensor comprises a first layer having a dual nanohole structure and a second layer having at least one nanopore. In some embodiments, the first and second layer define a chip of the sensor. In another aspect, methods of sensing are described herein, which in some embodiments comprise (i) providing a test sample comprising complexed and/or non-complexed biomolecules; (ii) contacting the test sample with the first layer of the molecular sensor; (iii) irradiating the dual nanohole structure of the sensor with a beam of electromagnetic radiation; (iv) optically trapping the biomolecules in the dual nanohole structure and measuring a surface plasmon resonance; (v) applying an electric field across the nanopore of the sensor; and (vi) measuring change in current across the nanopore during one or more translocation events of the biomolecules.

Abstract: Membrane materials and methods are disclosed for selectively separating or transporting ions in liquid media. In embodiments, the membranes comprise cellulose acetate polymer films having high cation, monovalent/divalent, and/or Li+/Mg2+ selectivity. Systems and methods for use of such membranes, including the direct extraction of lithium (DLE) from natural brines and other resources, also are disclosed.

Abstract: Provided herein are compositions, such as, for example, CXCL 10-secreting antigen presenting cells, and methods for ultrasound-induced blood-brain bander disruption (e.g., low-intensity pulsed ultrasound (LIPU)) to treat a brain cancer in a mammalian subject.

Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.

Abstract: Methods and devices for microfluidic detection of a biological maker in a biospecimen collected from a subject are disclosed. The microfluidic devices include nanoparticle-based nanosensors comprising supramolecular recognition sequences, protease consensus sequences, post-translationally modifiable sequences, or sterically hindered benzylether bonds for specific interaction with a biological marker. Also disclosed are particular nanosensors for detecting cytokines, and other proteins based upon supramolecular recognition without chemical modification or enzymatic cleavage.

Abstract: Described herein are novel lipid compositions comprising unsaturated dendrimers and methods of synthesis of unsaturated dendrimers. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Also described herein are pharmaceutical formulations comprising an unsaturated dendrimer, a lipid composition, and a therapeutic agent. Further described in here are methods of mRNA delivery comprising a lipid composition and a therapeutic agent. Further described herein are high-potency dosage forms of a therapeutic formulated with a lipid composition.

Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: Disclosed herein are electrolytes and electrochemical devices. The electrochemical devices comprise cathodes that include nickel-rich layered lithium transition metal oxides, lithium-rich layered transition-metal oxides, lithium manganese-based spinel oxides, lithium polyanion-based compounds, and combinations thereof. The electrolytes include a lithium imide salt, an aprotic acyclic carbonate solvent, and an additive, wherein the additive comprises a metal salt, an aprotic solvent, or a combination thereof. The electrolyte can be stable at a voltage of 4.3 V or above vs. Li/Li+.

Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: Systems, apparatuses, and methods provide various progressive, bit-level representations of digital data that are useful for a variety of systems and applications within the fields of machine learning, signal and data processing, and data analytics. Systems, apparatus, and methods for such representations incorporate one or more systems for machine learning, predicting, compressing and decompressing data, and are progressive such that the representations embody a sequential organization of information that prioritizes more information over less significant information. Embodiments of the present disclosure include systems for denoising, enhancing, compressing, decompressing, storing, and transmitting digitized media such as text, audio, image, and video. Methods can include partitioning data, modeling partitioned data, predicting partitioned data, transforming partitioned data, analyzing partitioned data, organizing partitioned data, and partially or fully restructuring the original data.

Abstract: The present disclosure relates to polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and results in a change in fluorescence based upon the particular pH. In some aspects, the disclosure also provides methods of using the polymers for the imaging of cellular or extracellular environment or delivering a drug.

Abstract: The present disclosure provides ammonium compounds, e.g., compounds according to Formula I as set forth herein, which are useful as antimicrobial agents. Methods for the treatment of bacterial infections and associated conditions, e.g., gastrointestinal conditions, are also described, as well as methods for altering the microbiome of subjects such as humans.

Abstract: Provided is a method of making a preliposomal Annamycin lyophilizate, the composition made by the method, and the use of the composition made thereby in the treatment of cancer.

Abstract: Aspects of the present disclosure are directed to methods for treating a subject having cancer. Certain aspects relate to treating a subject for lung cancer by administering poziotinib to a subject determined, from analysis of tumor DNA from the subject, to have an EGFR mutation of a particular classification. Further aspects relate to methods for treating a subject for lung cancer by detecting an EGFR mutation of a particular classification in tumor DNA from the subject and administering an effective amount of poziotinib to the subject. Also disclosed are methods for stratifying and prognosing subjects based on EGFR mutation classification.

Abstract: Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided.